COMT Activity and Hypnotizability
NCT: NCT04624880 · COMPLETED
Brief Summary
Hypnosis is an effective pain management tool for surgery that can reduce opioid use up to 40%. COMT single nucleotide polymorphisms (SNPs) can predict pain sensitivity and opioid use perioperatively, and may also be associated with hypnotizability or response to hypnotic analgesia. Analyzing COMT haplotypes from DNA extracted from saliva or blood using a giant magnetoresistive (GMR) nanotechnology platform may be faster, less expensive, and at least as accurate as pyrosequencing. This study aims to validate a multi-SNP point-of-care (POC) GMR assay for the rapid genotyping of SNPs predictive of COMT activity, and test the feasibility of using COMT activity as a biomarker for hypnotizability and/or response to hypnotic analgesia.
Frequently Asked Questions
What is COMT Activity and Hypnotizability?
COMT Activity and Hypnotizability is a clinical trial registered under NCT04624880. Current status: COMPLETED.
What is the status of NCT04624880?
The current status of NCT04624880 (COMT Activity and Hypnotizability) is: COMPLETED.
When did COMT Activity and Hypnotizability start?
COMT Activity and Hypnotizability started on 2021-01-13.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.